iPSC Reprogramming & Lineage Landscape 2006–2026 Clinical Era

Waddington Epigenetic Potential Engine & Pluripotent Quality Control Workbench
⛰️ Waddington Epigenetic Potential Landscape
Day: 14.0 / 14 Days
Potential Height: Low (Chromatin Open)
Triad Lock: Active (Oct4-Sox2-Nanog)
Somatic (Fibroblast)
MET Intermediates
Pluripotent (iPSC)
Differentiated Target
Oct4 (POU5F1) 1.0
Sox2 1.0
Klf4 0.8
c-Myc 0.5
🧬 Quantitative Reprogramming Telemetry
Batch: IPSC-2026-NATURE-RUN74
Nanog Activation Day 8.5
Reprogramming Efficiency 3.42%
Residual Pluripotency Purity 99.98%
Target Yield (Viable Cells) 4.85 M
Reprogramming Status: Somatic fibroblasts have traversed mesenchymal-to-epithelial transition (MET) and locked endogenous Nanog-Oct4-Sox2 circuitry at Day 8.5.

🏥 Clinical Manufacturing & Safety Assay Low / Cleared (<0.001%)

Anti-TRA-1-60 / CD30 Depletion: Applied
Clinical Release Criteria: Residual undifferentiated iPSC frequency must not exceed 1 in 100,000 cells to prevent teratoma formation post-engraftment. Current clearance level: Low / Cleared (<0.001%).
Enjoy this tool? Build your own with Super